ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
Provided By PR Newswire
Last update: Mar 27, 2025
Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025
Read more at prnewswire.com
